Portfolio company
Ambros Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage biotechnology company develops neridronate as a therapy for patients suffering from complex regional pain syndrome type 1.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Synerkine Pharma
This company develops fusion protein therapeutics to treat chronic pain and peripheral neuropathy for patients with inflammatory and neurodegenerative conditions.
NeurOdys Therapeutics
This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.
Nervonik
This company develops miniaturised peripheral nerve stimulation implants and wireless power systems for patients suffering from chronic neuropathic pain.
Hoba Therapeutics
This biotech company develops therapeutic proteins and non-opioid compounds to treat patients suffering from chronic neuropathic pain and sensorineural hearing loss.
Neuromodulation
This company develops miniaturised peripheral nerve stimulation implants and wireless power systems to treat patients suffering from chronic neuropathic pain.
Hoba Therapeutics ApS
This biotech company develops therapeutic proteins to treat patients suffering from chronic neuropathic pain and sensorineural hearing loss.
AMYL THERAPEUTICS
The company develops pan-amyloid immunotherapies to treat patients with neurodegenerative and rare diseases caused by toxic protein aggregates.
Convelo Therapeutics
This biotechnology company develops medicines to regenerate nerve cell myelin for patients with neurological disorders, including multiple sclerosis and paediatric leukodystrophies.